Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma

NCT07913594 is registered in ClinicalTrials.gov with Olivia Newton-John Cancer Research Institute as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07913594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
Lead sponsor
Olivia Newton-John Cancer Research Institute
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
December 31, 2030
Enrollment
25 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma refractory

Arms

As registered; 1 arm.

  • Zilovertamab vedotin (1.75mg/kg) Q3W + Lenalidomide (15mg p.o. 14 days) ExperimentalLenalidomide, Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg

    Induction phase:

    Zilovertamab vedotin (1.75mg/kg) will be administered using a 30-minute IV infusion on Day 1 of Cycle 1, and then on Day 1 of each 3-week (21-day) cycle, for up to 6 cycles. Capsules of lenalidomide (15mg) will be administered orally (p.o) on planned dosing days (14 days per cycle) for up to 6 cycles.

    Participants will have FDG PET/CT scans at the start of the study, prior to induction treatment and following cycle 2 and 6. Response assessments will be undertaken according to Lugano criteria. Participants achieving an objective response will continue onto maintenance phase.

    Maintenance phase:

    Lenalidomide treatment (15mg p.o, 14 days of a 21 day cycle) for up to 6 additional cycles.

    After finishing treatment, participants will attend follow-up visits every 3 months for up to 24 months.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Rate of complete response to up to 6 cycles of combination zilovertamab vedotin and lenalidomide Up to 18 weeks.

    Rate of complete response to up to 6 cycles of combination zilovertamab vedotin and lenalidomide as determined by first documented disease progression per Lugano response criteria.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • LENALIDOMIDE 3 Orange Book patentsPatent cliff March 8, 2028 (Orange Book patent)
    • US 8741929; expires March 8, 2028; assignee Celgene (United States)
    • US 7465800; expires April 27, 2027; assignee Celgene (United States)
    • US 5635517; expires October 4, 2019; assignee Celgene (United States)

Lead sponsor's other trials

Olivia Newton-John Cancer Research Institute, most recent start first.

Similar trials

Same condition (Recurrence) and phase, most recent start first.